How to buy Mesoblast (MSB) shares in Australia
Learn how to easily invest in Mesoblast shares.
Mesoblast is a biotechnology business based in Australia. Mesoblast shares (MSB) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Mesoblast has a trailing 12-month revenue of around $7.5 million. If you're looking to buy shares, check out the steps below.
How to buy shares in Mesoblast
- Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the ASX. Our table can help you choose.
- Open and fund your brokerage account. Complete an application with your personal and financial details, such as your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
- Search for Mesoblast. Find the share by name or ticker symbol: MSB. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Mesoblast reaches your desired price. Look into dollar-cost averaging to spread out your risk, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At today's price, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
- Check on your investment. Congratulations, you own a part of Mesoblast. Optimise your portfolio by tracking how your stock and the business performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that affect your stock.
Mesoblast stock price (ASX:MSB)Use our graph to track the performance of MSB stocks over time.
Mesoblast shares at a glance
|52-week range||$0.34 - $1.425|
|50-day moving average||$0.3725|
|200-day moving average||$0.7873|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-0.18|
Compare share trading platforms
Is it a good time to buy Mesoblast stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Mesoblast price performance over time
|1 week (2023-11-23)||2.53%|
|1 month (2023-11-03)||9.46%|
|3 months (2023-09-01)||-11.96%|
|6 months (2023-06-02)||-61.97%|
|1 year (2022-12-02)||-63.35%|
|2 years (2021-12-03)||-73.95%|
|3 years (2020-12-03)||-90.49%|
|5 years (2018-12-03)||-69.55%|
|Revenue TTM||$7.5 million|
|Gross profit TTM||$-47,421,000|
|Return on assets TTM||-6.51%|
|Return on equity TTM||-16.4%|
|Market capitalisation||$321.6 million|
TTM: trailing 12 months
Mesoblast share dividends
We're not expecting Mesoblast to pay a dividend over the next 12 months.
Have Mesoblast's shares ever split?
Mesoblast's shares were split on a 299:296 basis on 29 August 2017. So if you had owned 296 shares the day before the split, the next day you would own 299 shares. This wouldn't directly have changed the overall worth of your Mesoblast shares – just the quantity. However, indirectly, the new 1% lower share price could have impacted the market appetite for Mesoblast shares which in turn could have impacted Mesoblast's share price.
Mesoblast share price volatility
Over the last 12 months, Mesoblast's shares have ranged in value from as little as $0.34 up to $1.425. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Mesoblast's is 2.595. This would suggest that Mesoblast's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.
Stocks similar to Mesoblast
Frequently asked questions
More guides on Finder
How to buy OpenAI stock in Australia
Looking to jump on the AI bandwagon? Here's how you can invest in ChatGPT and its parent company OpenAI from Australia.
Best performing stocks on the ASX in 2023 (Updated weekly)
Looking for the best performing stocks in Australia? We update this list weekly.
Cryptocurrency ETFs explained: A simple guide for investors (2023)
If you’re looking for ways to gain exposure to Bitcoin and other digital currencies, cryptocurrency ETFs could be worth exploring. Find out what crypto ETFs are and how they work in this introductory guide.
How to buy Gol Linhas Aereas Inteligentes SA ADR (GOL) shares in Australia
Steps to owning and managing Gol Linhas Aéreas Inteligentes SA shares from Australia.
How to buy Microsoft (MSFT) shares in Australia
Steps to owning and managing Microsoft shares from in Australia.
A beginner’s guide to Lego investing
Looking for alternative investments? With a ROI of up to 3,593% lego may be worth considering. Read on to find out which lego sets are worth the investment.
The cheapest stock brokers in Australia (Dec 2023)
Find cheap stock brokerage in Australia when buying and selling shares on the ASX and other international exchanges.
What is the money market?
Learn about the money market and everyday consumer money market products.
Is investing in crowdfunding a safe investment?
Equity crowdfunding offers a unique opportunity for investors and for Australian startups, but Australia’s regulatory framework surrounding crowdfunding still lags behind the rest of the world.
The best trading platforms in Australia for 2023
Follow these tips to find the best share trading platform for you.
Ask an Expert